{"entity":{"id":"good-manufacturing-practice","kind":"term","name":"Good manufacturing practice (GMP)","aka":["GMP","current good manufacturing practice"],"tldr":"Good manufacturing practice is the set of controls over people, materials, equipment, procedures and records that is meant to make each batch of a medicine consistently as it should be. It is a property of how a product is made, not a finding about whether the treatment works.","summary":"The US Food and Drug Administration describes current good manufacturing practice (CGMP) as systems that assure proper design, monitoring and control of manufacturing processes and facilities, including quality management systems, suitable raw materials, written operating procedures, detection and investigation of deviations, and reliable testing laboratories; the 'C' stands for current, meaning technologies and systems must be up to date. FDA's quality-systems guidance gives a quality unit the job of reviewing procedures, evidence and departures from the intended process. Requirements depend on stage: most phase 1 investigational drugs are exempt from 21 CFR part 211 under 21 CFR 210.2(c), but FDA's 2008 phase 1 guidance applies CGMP under section 501(a)(2)(B) of the Food, Drug, and Cosmetic Act to them, so 'investigational' does not mean quality controls are optional. A passing final test does not close the process question: an unexplained substitution or missing record needs its own documented assessment. GMP concerns how a product is made; the product dossier (chemistry, manufacturing and controls), the decision on one lot (batch release) and clinical evidence answer different questions.","asOf":"2026-11-10","links":[{"label":"FDA: facts about the current good manufacturing practice (CGMP)","url":"https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practice-cgmp"},{"label":"FDA: quality systems approach to pharmaceutical CGMP regulations (September 2006)","url":"https://www.fda.gov/media/71023/download"},{"label":"FDA: current good manufacturing practice for phase 1 investigational drugs (July 2008)","url":"https://www.fda.gov/media/70975/download"}],"tags":[],"related":["pharmaceutical-gmp-inspections","radiopharmaceutical-gmp-release","cdmo","batch-release"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Good manufacturing practice concerns the quality system of people, procedures, materials, equipment and records. Batch release concerns the decision about one lot, while cell and gene products require product-specific release and potency evidence. These related questions are not interchangeable.","GMP combines people, procedures, materials, equipment and records into a working quality system. FDA's CGMP page says it covers quality management systems, quality raw materials, written operating procedures, detection and investigation of deviations and reliable testing laboratories, and that the C stands for current, requiring technologies and systems that are up to date. A clean room is one part of the system and not proof of compliance by itself.","In-process controls and the final sample. FDA's quality-systems guidance describes quality control as assessing incoming components, in-process materials and finished product and evaluating how the manufacturing process performs. A final sample answers a narrower question about tested material and cannot reconstruct an unrecorded process, so a passing final test does not close the question raised by, for example, an unexplained material substitution.","The quality unit approves or rejects incoming materials, in-process materials and drug products, reviews production records and investigates unexplained discrepancies. Investigating a deviation asks what happened, which material may be affected and how to prevent recurrence; a missing record and a failed test are different findings that both need an explanation.","Changes need control, because replacing a supplier or a processing step may alter the product. Q5E-style comparability asks whether relevant quality remains comparable; it does not assume that a familiar product name means unchanged biology.","Stage. Most phase 1 investigational drugs are exempt from 21 CFR part 211 under 21 CFR 210.2(c), and FDA's 2008 guidance applies CGMP under section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act to them, so investigational does not mean quality controls are optional. GMP supports reliable clinical investigation; it does not show efficacy."],"provenance":{"editedBy":"OnCo education audit","editedOn":"2026-11-10"},"category":"Regulation & policy"},"route":"/terms/good-manufacturing-practice/","neighbours":{"technology":[{"id":"cell-therapy-release-testing","kind":"technology","name":"Cell-therapy release and potency testing","route":"/technologies/cell-therapy-release-testing/"},{"id":"pharmaceutical-gmp-inspections","kind":"technology","name":"GMP, inspections, Form 483s and warning letters","route":"/technologies/pharmaceutical-gmp-inspections/"},{"id":"mrna-lnp-manufacturing","kind":"technology","name":"mRNA and lipid nanoparticle manufacturing","route":"/technologies/mrna-lnp-manufacturing/"},{"id":"radiopharmaceutical-gmp-release","kind":"technology","name":"Radiopharmaceutical GMP and releasing a drug that decays","route":"/technologies/radiopharmaceutical-gmp-release/"}],"term":[{"id":"batch-release","kind":"term","name":"Batch release (lot disposition)","route":"/terms/batch-release/"},{"id":"cdmo","kind":"term","name":"CDMO (contract development and manufacturing organisation)","route":"/terms/cdmo/"},{"id":"platform-vs-personalized-components","kind":"term","name":"Platform and personalised components of a product","route":"/terms/platform-vs-personalized-components/"}]}}